Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03738332 |
Recruitment Status :
Active, not recruiting
First Posted : November 13, 2018
Last Update Posted : September 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer Lymphedema Fibrosis | Device: Low-Level Laser | Not Applicable |
Primary aim:
To determine the feasibility of the use of LLLT for HNC survivors with lymphedema, specifically to 1) obtain recruitment estimates and determine barriers to recruitment; 2) identify barriers to implementation; 3) assess safety; and 4) evaluate patient satisfaction.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 25 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Pre-and post design |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study |
Actual Study Start Date : | February 25, 2019 |
Estimated Primary Completion Date : | December 31, 2020 |
Estimated Study Completion Date : | December 31, 2020 |

Arm | Intervention/treatment |
---|---|
Low-level laser therapy
Single arm
|
Device: Low-Level Laser
Low-level laser therapy |
- Recruitment rate [ Time Frame: Up to 12 months ]Recruitment rate and barriers to recruitment
- Completion rate [ Time Frame: Up to 12 months ]Barriers to completion of the study intervention
- Safety - adverse events rate [ Time Frame: Up to 12 months ]Adverse events
- Patient satisfaction rate [ Time Frame: Up to 12 months ]Patient satisfaction rate

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- >18 years of age
- Completion of either postoperative radiation or chemoradiation therapy
- No evidence of cancer
- Having head and neck external lymphedema
- Either completion of lymphedema therapy or not in active lymphedema therapy
- Ability to speak and read English
- Able to provide informed consent
Exclusion Criteria:
Patients will be excluded if they have any of the following medical conditions that would prohibit the safe implementation of LLLT: pregnancy; photosensitivity; chronic inflammatory diseases; venous thrombosis; history of severe trauma; medication that affects body fluid and electrolyte balance; use of high doses of non-steroidal anti-inflammatory drugs; or pre-existing skin rash, ulceration, open wound in the treatment area; and allergic and other systemic skin diseases.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03738332
United States, Pennsylvania | |
University of Pennsylvania Abramson Cancer Center | |
Philadelphia, Pennsylvania, United States, 19104 |
Responsible Party: | Jie Deng, Associate Professor, PhD, University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT03738332 |
Other Study ID Numbers: |
UPCC12318 |
First Posted: | November 13, 2018 Key Record Dates |
Last Update Posted: | September 2, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Lymphedema Lymphatic Diseases |